title: Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome.
abstract: Our aim was to determine the incidence of prediabetes and risk of developing cardiovascular disease (CVD) in women with polycystic ovary syndrome (PCOS). This prospective, observational study included 148 women with PCOS, without Type 2 diabetes mellitus (T2DM) and CVD present at baseline. In the fasting blood samples, we measured lipids, glucose, and insulin levels during oral glucose tolerance test, levels of C-reactive protein (CRP), steroids, 25-hydroxyvitamin D (25-OHD), prolactin, thyroid-stimulating hormone, and parathyroid hormone. The follow-up period was 3 years. At baseline, prevalent prediabetes was present in 18 (12%) of PCOS cases and it progressed to T2DM in 5 (3%) of the cases. Incident prediabetes during the follow-up was noted in 47 (32%) women or 4.7 per 1000 persons/year. Prediabetes was associated with elevated body mass index (BMI) (odds ratio [OR] = 1.089, confidence interval [CI]: 1.010; 1.174, p = 0.026), high baseline levels of CRP (OR = 3.286, CI: 1.299; 8.312, p = 0.012), homeostatic model assessment - insulin resistance (IR) (OR = 2.628, CI: 1.535; 4.498, p < 0.001), and high lipid accumulation product (LAP) (OR = 1.009, CI: 1.003; 1.016, p = 0.005). Furthermore, prediabetes was associated with low 25-OHD (OR = 0.795, CI: 0.724; 0.880, p ≤ 0.05). In addition, cardiovascular risk in PCOS women with prediabetes was high (hazard ratio = 1.092, CI: 1.036; 1.128, p < 0.001). We showed association of prediabetes with high BMI, IR, markers of inflammation, LAP, and low serum 25-OHD concentration. IR appears to be more relevant than the other predictors of prediabetes risk in this study. PCOS women are considered as a high-risk population for prediabetes.
authors.affiliation: Department of Nuclear Medicine and Endocrinology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina. zelijav@gmail.com.
authors.forename: Zelija
authors.initials: Z
authors.lastname: Velija-Asimi
authors.forename: Azra
authors.initials: A
authors.lastname: Burekovic
authors.forename: Tanja
authors.initials: T
authors.lastname: Dujic
authors.forename: Amela
authors.initials: A
authors.lastname: Dizdarevic-Bostandzic
authors.forename: Sabina
authors.initials: S
authors.lastname: Semiz
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood; D015994:Incidence; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000453:epidemiology*; D011236:Prediabetic State / Q000453:epidemiology* / Q000209:etiology*; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006887:Hydroxycholecalciferols; D008055:Lipids